Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Sodium zirconium cyclosilicate
Drug ID BADD_D02521
Description Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that acts as a highly selective potassium removing agent.[L2933] It is administered orally and is odorless, tasteless, and stable at room temperature.[L2933] Approval of the medication is supported by data from three double-blind, placebo-controlled trials and two open-label trials which showed that the onset of action was approximately 1.0 hour and the median time to achieving normal potassium levels in the blood was 2.2 hours, with 92% of patients achieving normal potassium levels within 48 hours following administration.[L2933] The treatment effect was maintained for up to 12 months.[L2933]
Indications and Usage Sodium zirconium cyclosilicate is a potassium binder indicated for the treatment of hyperkalemia in adult patients [FDA Label, F130].
Marketing Status Not Available
ATC Code V03AE10
DrugBank ID DB14048
KEGG ID D10727
MeSH ID C000597310
PubChem ID 92042806
NDC Product Code 65977-0132; 0310-1110; 0310-2111; 0310-1105
Synonyms sodium zirconium cyclosilicate | ZS-9 compound | Lokelma
Chemical Information
Molecular Formula H26Na2O20Si3Zr
CAS Registry Number 17141-74-1
SMILES O.O.O.O.O.O.[OH-].[OH-].O[Si](O)(O)O.O[Si](O)(O)O.O[Si](O)(O)O.[Na+].[Na+].[Zr]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.0010.017494%Not Available
Blood potassium abnormal13.11.01.0240.008747%Not Available
Blood potassium increased13.11.01.0110.008747%Not Available
Blood pressure increased13.14.03.0050.011662%Not Available
Cardiac failure02.05.01.0010.001521%
Cardiac failure congestive02.05.01.0020.008747%Not Available
Fluid overload14.05.06.001; Available
Fluid retention20.01.02.003; Available
Heart rate increased13.14.04.0020.005831%Not Available
Joint swelling15.01.02.0040.005831%Not Available
Oedema14.05.06.010; Available
Oedema peripheral14.05.06.011;;
Rash23.03.13.0010.005831%Not Available
Rash pruritic23.03.12.0020.005831%Not Available
Swelling08.01.03.0150.005831%Not Available
Weight increased13.15.01.0060.017494%
Peripheral swelling08.01.03.053; Available
The 1th Page    1    Total 1 Pages